Risperdal Gynecomastia Suits Receive Trial Dates Through 2015

Published on October 7, 2014 by Laurie Villanueva

Text-Size:A A A+


Risperdal lawsuit filings that allege gynecomastia, a serious side effect referring to male breast development, are moving closer to trial in Pennsylvania state court, where a round of hearings has been scheduled through next year.

According to recent reports, the first trial will begin on November 3, the second on January 3rd, 2015 and the third in February 2015. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals have been accused in these lawsuits, as well as 800 others now pending in the Philadelphia Court of Common Pleas, of withholding knowledge about the medication’s side effects, and overstating its benefits. Men and young boys claim to not have been made aware of Risperdal gynecomastia complications, which may manifest in tenderness and swelling in the breasts and necessitate liposuction or a mastectomy.

Plaintiffs in Risperdal lawsuits also allege that Johnson & Johnson and Janssen promoted Risperdal for purposes not cleared by the federal agency. This antipsychotic medication is currently approved by the U.S. Food and Drug Administration (FDA) to treat bipolar disorder and schizophrenia in adults and adolescents, among other conditions, as well as irritability in children with autism.

J&J Quietly Settles Risperdal Suits

Aside from lawsuits now pending in Philadelphia, court records indicate that Johnson & Johnson and its subsidiary have already settled a number of claims in Philadelphia state court. In September 2012, this was the case for a 21-year old man who allegedly suffered severe psychological trauma as a child when he developed Risperdal breasts and had to undergo a mastectomy.

A number of settlement agreements were reached shortly after that, after being filed on behalf of five boys who raised similar allegations against the makers of Risperdal.

At the end of last year, Johnson & Johnson agreed to a much larger settlement—this one involving the federal government. According to court records, the company resolved claims from the U.S. Department of Justice that they promoted Risperdal and other medications off-label for years, and withheld information about gynecomastia and other side effects. The agreement was reached in November 2013 for more than $2.2 billion.

Considering a Risperdal Lawsuit? Call Us.

If you or a man you love developed breasts after taking Risperdal, the time is now to file a lawsuit. Call the attorneys at Bernstein Liebhard LLP to find out if you are eligible to pursue a claim against Johnson & Johnson and Janssen: .